Observation à l'urgence pour le trouble lié à l'utilisation d'opioïdes
Mesurer l'amélioration de la qualité du traitement initié par les services d'urgence pour les troubles liés à l'utilisation d'opioïdes à l'aide de l'observation
This is a multicenter, randomized clinical comparative effectiveness trial (RCT) in which patients with untreated OUD presenting to a Northwell Health Emergency Department (ED), NYULH-Brooklyn, NYULH-Tisch, and Bellevue Hospital will be randomized (1:1) to be managed clinically through either a standard ED visit or an extended visit through ED observation (EDOU).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
In this hybrid implementation-effectiveness study, there is no direct research intervention. Rather, clinical care with well-documented effectiveness will be delivered at the discretion of clinical staff guided by clinical protocols for the management of OUD with MOUD (Medications for Opioid Use Disorder) introduced at each site prior to study enrollment. Enrolled patients will be randomized to ED vs. EDOU and to participate in assessments conducted at the index visit and at 30 days and 90 days. Patient level data will also be matched with Medicaid claims data for more robust analyses and to support the development of clinical quality measures.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New Jersey
-
Newark, New Jersey, États-Unis, 07103
- Rutgers University-University Hospital
-
-
New York
-
Brooklyn, New York, États-Unis, 11220
- NYULH-Brooklyn
-
New Hyde Park, New York, États-Unis, 11040
- Northwell Health - Long Island Jewish Medical Center
-
New York, New York, États-Unis, 10016
- Bellevue
-
New York, New York, États-Unis, 10016
- NYULH-Tisch
-
Staten Island, New York, États-Unis, 10305
- Northwell Health - Staten Island University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Is 18 years of age or older
- Is able to speak English sufficiently to understand study procedures
- Has a history of non-medical opioid use
- Is a potential candidate for ED-based MOUD treatment initiation and referral at the site as confirmed by clinical staff
- s not receiving MOUD through ongoing formal addiction treatment or pain management at the time of index ED visit
- Is willing to receive either standard ED care or enhanced ED care in EDOU depending on random assignment
- Presents to the ED during study screening hours
Exclusion Criteria:
- Unwilling or unable to provide written/electronic informed consent/HIPAA Authorization for research procedures, including research visits at baseline and Day 30 and Day 90, and/or consent for the release of health records and data matching for a period of 2 years following enrollment and 1 year prior to enrollment.
- Currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or that could prevent participation in the study
- Presents from a medical-based extended care facility (e.g., skilled nursing facility)
- Previous participation in the current study
- Inadequate locator information (unable or unwilling to provide one unique mean of contact).
- Has acute, severe medical, psychiatric, or concurrent substance use problem or meets other criteria that would exclude the patient (clinically) from placement in EDOU according to EDOU placement clinical protocols.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Standard visit
Participants will have standard Emergency Department visit as per standard operating procedures which should last approximately 3 -5 hours. |
Standard visit |
|
Expérimental: Extended visit with Observation
Participants will have extended Emergency Department visit by having an observation (which could be up to 23 hours) time in addition to the standard ED visit. In addition, information will be gathered about about the participants, use of opioids, healthcare visits, the quality of health, life, and treatment, and other topics. Urine or saliva or both may also be collected. |
Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED. Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants who receive Emergency Department (ED)-initiated Buprenorphine (BUP)
Délai: Week 1 (~7-10 days)
|
Receipt of ED-initiated BUP will be operationally defined to include administration of BUP and/or prescription for BUP as part of the ED/Emergency Department Observation (Units) (EDOU) visit. This measure will be abstracted from the health record primarily. |
Week 1 (~7-10 days)
|
|
Proportion of participants who receive ED-initiated or ED-expedited BUP
Délai: Week 1 (~7-10 days)
|
Receipt of ED-initiated/expedited BUP will be operationally defined to include the provision of a specific "warm" referral or transfer of care to a provider, clinic, or treatment setting with the capacity to administer and/or prescribe BUP within 24 hours of completion of the ED/EDOU visit. Eligible transition of care will be will described further in the Manual of Operations (MOP) and will include direct transport or handoff to an outpatient provider immediately from the ED, provision of an appointment within 24 hours (with a specific time and location), transfer to general inpatient or inpatient OUD/addiction treatment. Neither confirmation of a completed appointment (i.e., patient shows up and is seen) nor receipt of BUP at the dedicated follow-up appointment will be required as the patient and treating provider may elect to treat with alternative regimes (e.g., methadone, naltrexone). This measure will be abstracted from the health record primarily. |
Week 1 (~7-10 days)
|
|
Proportion of participants who receive ED-initiated or ED-expedited Medications for Opioid Use Disorder (MOUD)
Délai: Week 1 (~7-10 days)
|
Receipt of ED-initiated MOUD, inclusive of BUP, methadone, or naltrexone. |
Week 1 (~7-10 days)
|
|
The proportion of participants who are successfully linked to formal addiction treatment within one week following the completion of their index ED/EDOU visit
Délai: Week 1 (~7-10 days)
|
Successful linkage to formal addiction treatment will be defined as confirmed attendance at formal addiction treatment for OUD following completion of the ED/EDOU visit. Formal addiction treatment will be those treatments consistent with the American Society of Addiction Medicine's (ASAM) level of care (1-4) and will include a range of clinical settings, including office-based providers of BUP or naltrexone, Opioid Treatment Programs (OTPs), intensive outpatient, inpatient, or residential treatments. Means of confirmation will include direct contact with the facility and/or treating clinician or other objective means (e.g., medical record review). |
Week 1 (~7-10 days)
|
|
The proportion of participants who are confirmed to be engaged in formal addiction treatment for OUD on the 30th day following the completion of their index ED/EDOU visit
Délai: Day 30
|
Engagement in treatment for OUD will be defined as confirmed enrollment in formal addiction treatment for OUD on the 30th day following completion of the ED/EDOU visit. Attendance at two or more visits for formal addiction treatment within the 30-day period also constitutes engagement. |
Day 30
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changement dans la proportion de participants ayant obtenu un résultat positif aux opioïdes illicites/substances illicites
Délai: Baseline, Jour 30
|
Baseline, Jour 30
|
|
|
Modification de la proportion de participants ayant obtenu un résultat positif aux opioïdes/substances illicites
Délai: Jour 30, Jour 90
|
Jour 30, Jour 90
|
|
|
Évolution du nombre de surdoses et des comportements à risque
Délai: Ligne de base, Jour 30
|
Ligne de base, Jour 30
|
|
|
Modification du nombre de cas de surdosage et des comportements à risque
Délai: Jour 30, Jour 90
|
Jour 30, Jour 90
|
|
|
Modification de la proportion des participants ayant déclaré une satisfaction au traitement
Délai: Ligne de base, jour 30
|
Ligne de base, jour 30
|
|
|
Changement de la proportion de participants ayant déclaré une satisfaction au traitement
Délai: Jour 30, Jour 90
|
Jour 30, Jour 90
|
|
|
Change in number of days of opioid and other drug use
Délai: Baseline, Day 30
|
Measured by the Timeline Follow-Back (TLFB) procedure will be used to elicit the participant's self-reported use of illicit substances at baseline and throughout study participation. |
Baseline, Day 30
|
|
Change in number of days of opioid and other drug use
Délai: Day 30, Day 90
|
Measured by the Timeline Follow-Back (TLFB) procedure will be used to elicit the participant's self-reported use of illicit substances at baseline and throughout study participation. |
Day 30, Day 90
|
|
Change in score on EuroQol-5 Dimensions (EQ-5D) Scale
Délai: Baseline, Day 30
|
EuroQol-5 Dimensions (EQ-5D): The EuroQol is a structured interview that collects general health information applicable to a wide range of health conditions and treatment, providing a simple descriptive profile and a single index value for health status between 0 (dead) and 1 (full health). |
Baseline, Day 30
|
|
Change in score on EuroQol-5 Dimensions (EQ-5D) Scale
Délai: Day 30, Day 90
|
EuroQol-5 Dimensions (EQ-5D): The EuroQol is a structured interview that collects general health information applicable to a wide range of health conditions and treatment, providing a simple descriptive profile and a single index value for health status between 0 (dead) and 1 (full health). |
Day 30, Day 90
|
|
Change in Score on Patient-Reported Outcomes Measurement Information System (PROMIS-29) Scale
Délai: Baseline, Day 30
|
Assessment of quality of life in seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) all assessed using the PROMIS-29 questionnaire. PROMIS-29 is scored on a T-score metric with a mean of 50 and a standard deviation of 10 in the U.S. general population, with a higher score representing more symptoms. |
Baseline, Day 30
|
|
Change in Score on Patient-Reported Outcomes Measurement Information System (PROMIS-29) Scale
Délai: Day 30, Day 90
|
Assessment of quality of life in seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) all assessed using the PROMIS-29 questionnaire. PROMIS-29 is scored on a T-score metric with a mean of 50 and a standard deviation of 10 in the U.S. general population, with a higher score representing more symptoms. |
Day 30, Day 90
|
|
Change in score on Patient Health Questionnaire (PHQ)-9 Scale
Délai: Baseline, Day 30
|
The PHQ-9 is a 9-item instrument used for screening, diagnosing, monitoring and measuring the severity of depression. Each item is rated from 0 (not at all) to 3 (nearly every day). Total scores range from 0-27. Scores are interpreted as follows: Minimal Depression: 0-4, Mild depression: 5-9, Moderate depression: 10-14, Moderately severe depression: 15-19, Severe depression: 20-27. |
Baseline, Day 30
|
|
Change in score on Patient Health Questionnaire (PHQ)-9 Scale
Délai: Day 30, Day 90
|
The PHQ-9 is a 9-item instrument used for screening, diagnosing, monitoring and measuring the severity of depression. Each item is rated from 0 (not at all) to 3 (nearly every day). Total scores range from 0-27. Scores are interpreted as follows: Minimal Depression: 0-4, Mild depression: 5-9, Moderate depression: 10-14, Moderately severe depression: 15-19, Severe depression: 20-27. |
Day 30, Day 90
|
|
Change in score on Treatment Effectiveness Assessment (TEA) Scale
Délai: Baseline, Day 30
|
Treatment Effectiveness Assessment (TEA) scale is comprised of 4 questions about substance use, health, lifestyle, and community. Participants respond the questions on how they have improved in that area on a scale from 1 (not better at all) to 10 (very much better). Higher scores indicate overall improvement and effectiveness of treatment. |
Baseline, Day 30
|
|
Change in score on Treatment Effectiveness Assessment (TEA) Scale
Délai: Day 30, Day 90
|
Treatment Effectiveness Assessment (TEA) scale is comprised of 4 questions about substance use, health, lifestyle, and community. Participants respond the questions on how they have improved in that area on a scale from 1 (not better at all) to 10 (very much better). Higher scores indicate overall improvement and effectiveness of treatment. |
Day 30, Day 90
|
|
Change in proportion of participants who reported changes in social determinants of health (e.g., homelessness, employment)
Délai: Baseline, Day 30
|
Self reported by participants. |
Baseline, Day 30
|
|
Change in proportion of participants who reported changes in social determinants of health (e.g., homelessness, employment)
Délai: Day 30, Day 90
|
Self reported by participants. |
Day 30, Day 90
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Ryan McCormack, MD, NYU Langone Health
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20-01951
- 5R33DA049265-03 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Délai de partage IPD
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Critères d'accès au partage IPD
The investigator who proposed to use the data.Upon reasonable request. Requests should be directed to ryan.mccormack@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .